Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Cash & Equivalents (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Cash & Equivalents for 6 consecutive years, with $52.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 87.85% to $52.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $52.3 million, a 87.85% decrease, with the full-year FY2025 number at $52.3 million, down 87.85% from a year prior.
  • Cash & Equivalents was $52.3 million for Q4 2025 at Janux Therapeutics, up from $48.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $430.6 million in Q4 2024 to a low of $14.7 million in Q2 2024.
  • A 5-year average of $82.6 million and a median of $51.4 million in 2022 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 2142.15% in 2024, then crashed 87.85% in 2025.
  • Janux Therapeutics' Cash & Equivalents stood at $35.6 million in 2021, then soared by 44.53% to $51.4 million in 2022, then tumbled by 62.66% to $19.2 million in 2023, then surged by 2142.15% to $430.6 million in 2024, then plummeted by 87.85% to $52.3 million in 2025.
  • Per Business Quant, the three most recent readings for JANX's Cash & Equivalents are $52.3 million (Q4 2025), $48.4 million (Q3 2025), and $52.4 million (Q2 2025).